Zeposia is included in the high-cost protection with limitation

17 June 2022 - Zeposia (ozanimod) is included in the high-cost protection with limited subsidy from 17 June 2022.  ...

Read more →

Givlaari is included in the high-cost protection with limitation

17 June 2022 - Givlaari (givosiran) is included in the high-cost protection with limited subsidy to reduce attacks in patients with ...

Read more →

Subsidy for medicine for Duchenne muscular dystrophy expires

16 June 2022 - The TLV has decided that Translarna, which is subsidised for patients with Duchenne muscular dystrophy, will not ...

Read more →

TLV reconsiders subsidy of cyclin-dependent kinase 4/6 inhibitor Verzenios

8 June 2022 - Since April 2022, Verzenios has had market approval for the treatment of adult patients with early breast ...

Read more →

TLV reconsiders subsidy of the IL-17 and IL-23 inhibitors

2 June 2022 - The TLV has started a trial for the interleukin 17 and interleukin 23 inhibitors. ...

Read more →

Health economic assessment of Trodelvy in advanced triple negative breast cancer

23 May 2022 - TLV has produced a health economic assessment for the regions for the drug Trodelvy (sacituzumab govitecan).  ...

Read more →

TLV reconsiders subsidy of CGRP inhibitors

18 May 2022 - TLV has started a review of the CGRP inhibitors. ...

Read more →

Health economic assessment of Xevudy for the treatment of COVID-19

17 May 2022 - TLV has produced a health economic assessment for the regions for the drug Xevudy (sotrovimab).  ...

Read more →

Tepmetko is granted a temporary subsidy

16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy ...

Read more →

Health economic assessment of Abecma in the treatment of multiple myeloma

6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel).  ...

Read more →

Health economic assessment of Blenrep in the treatment of multiple myeloma

6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin).  ...

Read more →

New handbook on health economic assessments of medical devices

4 May 2022 - TLV performs health economic assessments of medical technology products at the request of the Medical Technology Product ...

Read more →

TLV submits proposals for increased access to new gene therapies

2 May 2022 - How should society handle new gene therapies for serious diseases, where the effect of the drugs is ...

Read more →

Health economic assessment of Leqvio in the treatment of high LDL cholesterol and mixed lipid disorders

26 April 2022 - The Swedish Dental and Pharmaceutical Benefits Agency has undertaken a health economic assessment of Leqvio (inclisiran) for ...

Read more →

Final reconciliation of savings from side agreements for the full year 2021

18 March 2022 - TLV has presented the final reconciliation to the government of the outcome of the rebates in ...

Read more →